2019
Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies
Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases And Sciences 2019, 64: 1016-1029. PMID: 30887150, DOI: 10.1007/s10620-019-05582-x.BooksConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaTreatment strategiesMulti-targeted tyrosine kinase inhibitorSystemic managementGeneral host factorsEffective systemic therapyInitial treatment strategyMulti-modal therapyOverall tumor burdenCancer-related deathNovel treatment strategiesTyrosine kinase inhibitorsDifferent treatment classesKey molecular targetsInoperable diseaseCheckpoint inhibitorsEmerging TherapiesMost patientsDurable cureSystemic therapyLandmark trialsTumor burdenTelomerase reverse transcriptaseTherapy
2016
Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology
Hart T, Dider S, Han W, Xu H, Zhao Z, Xie L. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Scientific Reports 2016, 6: 20441. PMID: 26841718, PMCID: PMC4740793, DOI: 10.1038/srep20441.Peer-Reviewed Original ResearchConceptsPrecision anti-cancer therapyMolecular basisAnti-cancer therapyStructural systems pharmacologyProtein-protein interactionsDrug target identificationNetwork biology analysisMolecular targetsInteractomic dataGenetic interactionsStructural proteomeGenetic networksKey molecular targetsPhenotypic responsesKinase targetsBiology analysisCancer mutationsPleiotropic effectsAnti-cancer effectsNetwork biomarkersTarget identificationGenetic biomarkersSystems pharmacology approachKey nodesTarget
2011
The Novel Antipsychotic Drug Lurasidone Enhances N-Methyl-d-aspartate Receptor-Mediated Synaptic Responses
Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The Novel Antipsychotic Drug Lurasidone Enhances N-Methyl-d-aspartate Receptor-Mediated Synaptic Responses. Molecular Pharmacology 2011, 81: 113-119. PMID: 22072817, PMCID: PMC3263951, DOI: 10.1124/mol.111.076141.Peer-Reviewed Original ResearchConceptsAtypical antipsychotic drugsEffect of lurasidoneSynaptic responsesVivo administrationN-methyl-D-aspartate (NMDA) receptor hypofunctionShort-term administrationCortical pyramidal neuronsAtypical APDsReceptor antagonist haloperidolAtypical APD clozapineKey molecular targetsSubchronic administrationPyramidal neuronsReceptor hypofunctionReceptor antagonismReceptor antagonistAntagonist haloperidolNMDAR responsesNMDAR synaptic functionAntipsychotic drugsNR2B subunitSerotonin 5Noncompetitive antagonistLurasidoneCognitive impairment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply